CONNECT WITH US
HealthTech

HealthTech

Why don't GLP‑1 obesity drugs work for everyone?

Medical Xpress logo

Published on

Add as a preferred source on Google
Why don't GLP‑1 obesity drugs work for everyone?

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Medications like Ozempic and Wegovy, which contain semaglutide—a GLP‑1 receptor agonist that helps regulate blood sugar, appetite and body weight—have become household names and important pillars in obesity management for the medical profession.

Research has shown GLP-1 medications reduce body weight by an average of 15% when used weekly for 68 weeks and combined with lifestyle interventions. This is because semaglutide acts on the brain to increase the feeling of fullness and to decrease appetite.

These medications don't work the same way for everyone, however. Our multidisciplinary research team at the University of Alberta is working to improve obesity care for people of all ages and to understand why some people respond better to semaglutide than others, and how their weight loss can be maintained over time.

We are investigating the role of energy metabolism as a potentially important piece in a complex puzzle.

Research has shown that semaglutide medications improve quality of life, blood markers such as sugar or cholesterol, strength and overall health. Weight loss is only one measure of how well they work.

We are exploring whether people's responses to these medications could lie in individual factors such as genetics, metabolism, body composition, lifestyle, microbiota, associated diseases, age and sex.

Energy metabolism may also be an important piece of this puzzle. This is a measure of the total calories consumed (in) and the total calories burned (out).


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.